{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:57:09Z","timestamp":1791194229753,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T00:00:00Z","timestamp":1333584000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1741-7015-10-33","type":"journal-article","created":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T10:14:26Z","timestamp":1333620866000},"source":"Crossref","is-referenced-by-count":75,"title":["Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis"],"prefix":"10.1186","volume":"10","author":[{"given":"Atle","family":"Fretheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Odgaard-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odd","family":"Br\u00f8rs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steinar","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Nj\u00f8lstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole F","family":"Norheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Svilaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivar S","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Th\u00fcrmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Flottorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,5]]},"reference":[{"key":"524_CR1","volume-title":"The Global Burden Of Disease: 2004 Update","author":"World Health Organization","year":"2008","unstructured":"World Health Organization: The Global Burden Of Disease: 2004 Update. 2008, Geneva: WHO"},{"key":"524_CR2","volume-title":"World Health Statistics 2008","author":"The World Health Organization","year":"2008","unstructured":"The World Health Organization: World Health Statistics 2008. 2008, Geneva: The World Health Organization"},{"key":"524_CR3","volume-title":"The World Health Report 2002 Reducing Risks, Promoting Healthy Lives","author":"The World Health Organization","year":"2002","unstructured":"The World Health Organization: The World Health Report 2002 Reducing Risks, Promoting Healthy Lives. 2002, Geneva: The World Health Organization"},{"key":"524_CR4","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0140-6736(90)90944-Z","volume":"335","author":"R Collins","year":"1990","unstructured":"Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990, 335: 827-838. 10.1016\/0140-6736(90)90944-Z.","journal-title":"Lancet"},{"key":"524_CR5","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"F Turnbull","year":"2003","unstructured":"Turnbull F: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003, 362: 1527-1535.","journal-title":"Lancet"},{"key":"524_CR6","doi-asserted-by":"publisher","first-page":"b1665","DOI":"10.1136\/bmj.b1665","volume":"338","author":"MR Law","year":"2009","unstructured":"Law MR, Morris JK, Wald NJ: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009, 338: b1665-10.1136\/bmj.b1665.","journal-title":"BMJ"},{"key":"524_CR7","first-page":"25","volume":"161","author":"JM Wright","year":"1999","unstructured":"Wright JM, Lee CH, Chambers GK: Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?. CMAJ. 1999, 161: 25-32.","journal-title":"CMAJ"},{"key":"524_CR8","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","volume":"289","author":"BM Psaty","year":"2003","unstructured":"Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS: Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003, 289: 2534-2544. 10.1001\/jama.289.19.2534.","journal-title":"JAMA"},{"key":"524_CR9","unstructured":"Hypertension: The clinical management of primary hypertension in adults (update). 2011, London: National Clinical Guidelines Centre at the The Royal College of Physicians"},{"key":"524_CR10","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","volume":"283","author":"ALLHAT Collaborative Research Group","year":"2000","unstructured":"ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000, 283: 1967-1975. 10.1001\/jama.283.15.1967. see comment Erratum: JAMA 2002, 288:2976","journal-title":"JAMA"},{"key":"524_CR11","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","volume":"364","author":"B Carlberg","year":"2004","unstructured":"Carlberg B, Samuelsson O, Lindholm LH: Atenolol in hypertension: is it a wise choice?. Lancet. 2004, 364: 1684-1689. 10.1016\/S0140-6736(04)17355-8.","journal-title":"Lancet"},{"key":"524_CR12","first-page":"CD002003","volume-title":"Cochrane Database Syst Rev","author":"CS Wiysonge","year":"2007","unstructured":"Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J: Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007, CD002003."},{"key":"524_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007, 369: 201-207. 10.1016\/S0140-6736(07)60108-1.","journal-title":"Lancet"},{"key":"524_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/archinternmed.2010.427","volume":"171","author":"S Sciarretta","year":"2011","unstructured":"Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M: Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med. 2011, 171: 384-394. 10.1001\/archinternmed.2010.427.","journal-title":"Arch Intern Med"},{"key":"524_CR15","volume-title":"Prim\u00e6rforebygging av hjerte- og karsykdom, med s\u00e6rlig vekt p\u00e5 medikamentelle tiltak","author":"L H\u00e5heim","year":"2008","unstructured":"H\u00e5heim L, Fretheim A, Br\u00f8rs O, Kjeldsen SE, Kristiansen IS, Madsen S, Nj\u00f8lstad I, Norheim OF, Ose L, Svilaas A, Flottorp S, Th\u00fcrmer H: Prim\u00e6rforebygging av hjerte- og karsykdom, med s\u00e6rlig vekt p\u00e5 medikamentelle tiltak. 2008, Oslo, Norway: Norwegian Knowledge Centre for the Health Services"},{"key":"524_CR16","doi-asserted-by":"publisher","first-page":"d3626","DOI":"10.1136\/bmj.d3626","volume":"343","author":"OF Norheim","year":"2011","unstructured":"Norheim OF, Gjelsvik B, Klemsdal TO, Madsen S, Meland E, Narvesen S, Negard A, Nj\u00f8lstad I, Tonstad S, Ulvin F, Wisl\u00f8ff T: Norway's new principles for primary prevention of cardiovascular disease: age differentiated risk thresholds. BMJ. 2011, 343: d3626-10.1136\/bmj.d3626.","journal-title":"BMJ"},{"key":"524_CR17","unstructured":"Fretheim A, Odgaard-Jensen J, Br\u00f8rs O, Flottorp S, Kristiansen IS, Nj\u00f8lstad I, Norheim OF, Svilaas A, Th\u00fcrmer H: Systematic Review and Multiple Treatment Meta-Analysis of Drug-Trials for Hypertension (protocol). PROSPERO 2011:CRD42011001066 Available from [ http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.asp?ID=CRD42011001066 ]"},{"key":"524_CR18","unstructured":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2004, NIH Publication No. 04-5230"},{"key":"524_CR19","first-page":"CD001841","volume-title":"Cochrane Database Syst Rev","author":"JM Wright","year":"2009","unstructured":"Wright JM, Musini VM: First-line drugs for hypertension. Cochrane Database Syst Rev. 2009, CD001841."},{"key":"524_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey SG, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315: 629-634. 10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"key":"524_CR21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/bmj.323.7308.334","volume":"323","author":"R Harbour","year":"2001","unstructured":"Harbour R, Miller J: A new system for grading recommendations in evidence based guidelines. BMJ. 2001, 323: 334-336.","journal-title":"BMJ"},{"key":"524_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0962280207080643","volume":"17","author":"G Salanti","year":"2008","unstructured":"Salanti G, Higgins JP, Ades AE, Ioannidis JP: Evaluation of networks of randomized trials. Stat Methods Med Res. 2008, 17: 279-301.","journal-title":"Stat Methods Med Res"},{"key":"524_CR23","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton N, Caldwell D, Ades A: Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010, 29: 932-944. 10.1002\/sim.3767.","journal-title":"Stat Med"},{"key":"524_CR24","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH: GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011, 64: 401-406. 10.1016\/j.jclinepi.2010.07.015.","journal-title":"J Clin Epidemiol"},{"key":"524_CR25","first-page":"312","volume":"36","author":"M Sun","year":"1997","unstructured":"Sun M, Zhou H, Jia Z: Prevention and treatment of stroke after hypertension for ten years in Hunan Province. Chinese. Zhonghua Nei Ke Za Zhi. 1997, 36: 312-314.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"524_CR26","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","unstructured":"SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991, 265: 3255-3264.","journal-title":"JAMA"},{"key":"524_CR27","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/0002-9343(80)90438-6","volume":"69","author":"A Helgeland","year":"1980","unstructured":"Helgeland A: Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med. 1980, 69: 725-732. 10.1016\/0002-9343(80)90438-6.","journal-title":"Am J Med"},{"key":"524_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00004872-198710000-00009","volume":"5","author":"L Wilhelmsen","year":"1987","unstructured":"Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, Hornkvist PE, Pennert K, Tuomilehto J, Wedel H: Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987, 5: 561-572. 10.1097\/00004872-198710000-00009.","journal-title":"J Hypertens"},{"key":"524_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.304.6842.1631-b","volume":"304","author":"S Peart","year":"1992","unstructured":"Peart S, Brennan PJ, Broughton P, Dollery C, Hudson MF, Lever AF, Meade TW, Rose GA, Greenberg G, Pocock SJ: Medical Research Council trial of treatment of hypertension in older adults: Principal results. BMJ. 1992, 304: 405-412.","journal-title":"BMJ"},{"key":"524_CR30","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanm\u00e4ki k, Dahl\u00f6f B, de Faire U, M\u00f6rlin C, Karlberg BE, Wester PO, Bj\u00f6rck J: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999, 353: 611-616. 10.1016\/S0140-6736(98)05012-0.","journal-title":"Lancet"},{"key":"524_CR31","doi-asserted-by":"crossref","unstructured":"Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Hypertension. 1999, 34: 1129-1133.","DOI":"10.1161\/01.HYP.34.5.1129"},{"key":"524_CR32","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","volume":"354","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999, 354: 1751-1756. 10.1016\/S0140-6736(99)10327-1.","journal-title":"Lancet"},{"key":"524_CR33","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002, 288: 2981-2997. 10.1001\/jama.288.23.2981. Erratum: JAMA 2003, 289:178","journal-title":"JAMA"},{"key":"524_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","volume":"356","author":"L Hansson","year":"2000","unstructured":"Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahl\u00f6f B, Karlberg BE: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000, 356: 359-365. 10.1016\/S0140-6736(00)02526-5.","journal-title":"Lancet"},{"key":"524_CR35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/01.HYP.0000057420.27692.AD","volume":"41","author":"G Mancia","year":"2003","unstructured":"Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, Wagener G, Ruilope LM: Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension. 2003, 41: 431-436. 10.1161\/01.HYP.0000057420.27692.AD.","journal-title":"Hypertension"},{"key":"524_CR36","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","volume":"359","author":"LIFE Study Group","year":"2002","unstructured":"LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002, 359: 1004-1010. 10.1016\/S0140-6736(02)08090-X.","journal-title":"Lancet"},{"key":"524_CR37","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMoa021716","volume":"348","author":"LM Wing","year":"2003","unstructured":"Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, Mcneil JJ, Macdonal GJ, Marley JE, Morga TO, West MJ, Second Australian National Blood Pressure Study Group: A comparison of outcomes with angiotensin-converting--enzyme inhibi-tors and diuretics for hypertension in the elderly. N Engl J Med. 2003, 348: 583-592. 10.1056\/NEJMoa021716.","journal-title":"N Engl J Med"},{"key":"524_CR38","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","volume":"289","author":"CONVINCE Research Group","year":"2003","unstructured":"CONVINCE Research Group: Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003, 289: 2073-2082. 10.1001\/jama.289.16.2073.","journal-title":"JAMA"},{"key":"524_CR39","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1097\/00004872-200312000-00030","volume":"21","author":"CJ Bulpitt","year":"2003","unstructured":"Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C, Nunes M, Peters R, Staessen JA, Thijs L, Hypertension in the Very Elderly Trial Working Group: Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens. 2003, 21: 2409-2417. 10.1097\/00004872-200312000-00030.","journal-title":"J Hypertens"},{"key":"524_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/08037050310009545","volume":"12","author":"E Malacco","year":"2003","unstructured":"Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, Coppini A: Treatment of isolated systolic hypertension: the SHELL study results. Blood Press. 2003, 12: 160-167. 10.1080\/08037050310009545.","journal-title":"Blood Press"},{"key":"524_CR41","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1291\/hypres.28.307","volume":"28","author":"H Suzuki","year":"2005","unstructured":"Suzuki H, Kanno Y: Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res. 2005, 28: 307-314. 10.1291\/hypres.28.307.","journal-title":"Hypertens Res"},{"key":"524_CR42","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA.107.098475","volume":"51","author":"T Ogihara","year":"2008","unstructured":"Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T: Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008, 51: 393-398. 10.1161\/HYPERTENSIONAHA.107.098475.","journal-title":"Hypertension"},{"key":"524_CR43","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/jama.1970.03170330025003","volume":"213","author":"Veterans Administration Cooperative Study Group on Antihypertensive Agents","year":"1970","unstructured":"Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970, 213: 1143-1152.","journal-title":"JAMA"},{"key":"524_CR44","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S0140-6736(85)91783-0","volume":"1","author":"A Amery","year":"1985","unstructured":"Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985, 1: 1349-1354.","journal-title":"Lancet"},{"key":"524_CR45","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1136\/bmj.293.6555.1145","volume":"293","author":"J Coope","year":"1986","unstructured":"Coope J, Warrender TS: Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed). 1986, 293: 1145-1151. 10.1136\/bmj.293.6555.1145.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"524_CR46","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/0140-6736(91)92589-T","volume":"338","author":"B Dahlof","year":"1991","unstructured":"Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991, 338: 1281-1285. 10.1016\/0140-6736(91)92589-T.","journal-title":"Lancet"},{"key":"524_CR47","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","volume":"350","author":"JA Staessen","year":"1997","unstructured":"Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997, 350: 757-764. 10.1016\/S0140-6736(97)05381-6.","journal-title":"Lancet"},{"key":"524_CR48","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","volume":"358","author":"NS Beckett","year":"2008","unstructured":"Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A. Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ: Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008, 358: 1887-1898. 10.1056\/NEJMoa0801369.","journal-title":"N Engl J Med"},{"key":"524_CR49","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Jua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004, 363: 2022-2031. 10.1016\/S0140-6736(04)16451-9.","journal-title":"Lancet"},{"key":"524_CR50","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/S0140-6736(07)60669-2","volume":"369","author":"S Mochizuki","year":"2007","unstructured":"Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007, 369: 1431-1439. 10.1016\/S0140-6736(07)60669-2.","journal-title":"Lancet"},{"key":"524_CR51","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008, 359: 2417-2428. 10.1056\/NEJMoa0806182.","journal-title":"N Engl J Med"},{"key":"524_CR52","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahlof","year":"2005","unstructured":"Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlson J, Nieminen M, O'Brien E, Otergren J: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005, 366: 895-906. 10.1016\/S0140-6736(05)67185-1.","journal-title":"Lancet"},{"key":"524_CR53","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1093\/eurheartj\/ehp363","volume":"30","author":"T Sawada","year":"2009","unstructured":"Sawada T, Yamada H, Dahlof B, Matsubara H: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J. 2009, 30: 2461-2469. 10.1093\/eurheartj\/ehp363.","journal-title":"Eur Heart J"},{"key":"524_CR54","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/00004872-198508000-00011","volume":"3","author":"The IPPPSH Collaborative Group","year":"1985","unstructured":"The IPPPSH Collaborative Group: Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. J Hypertens. 1985, 3: 379-392.","journal-title":"J Hypertens"},{"key":"524_CR55","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","volume":"21","author":"H Lithell","year":"2003","unstructured":"Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003, 21: 875-886. 10.1097\/00004872-200305000-00011.","journal-title":"J Hypertens"},{"key":"524_CR56","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/14017430310001186","volume":"37","author":"I Aursnes","year":"2003","unstructured":"Aursnes I, Tvete IF, Gasemyr J, Natvig B: Clinical efficacies of antihypertensive drugs. Scand Cardiovasc J. 2003, 37: 72-79. 10.1080\/14017430310001186.","journal-title":"Scand Cardiovasc J"},{"key":"524_CR57","doi-asserted-by":"publisher","first-page":"d4891","DOI":"10.1136\/bmj.d4891","volume":"343","author":"T Krause","year":"2011","unstructured":"Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, the Guideline Development Group: Guidelines: management of hypertension: summary of NICE guidance. BMJ. 2011, 343: d4891-10.1136\/bmj.d4891.","journal-title":"BMJ"},{"key":"524_CR58","unstructured":"National Collaborating Centre for Chronic Conditions. Hypertension: Management of Hypertension in Adults in Primary Care: Partial Update. 2006, London: Royal College of Physicians"},{"key":"524_CR59","unstructured":"Statens Beredning f\u00f6r Medicinsk Utv\u00e4rdering. M\u00e5ttligt F\u00f6rh\u00f6jt Blodtryck Uppdatering 2007. 2007, Stockholm: Statens beredning f\u00f6r medicinsk utv\u00e4rdering (SBU)"},{"key":"524_CR60","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0895-7061(99)00215-0","volume":"13","author":"T Ogihara","year":"2000","unstructured":"Ogihara T: Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am J Hypertens. 2000, 13: 461-467. 10.1016\/S0895-7061(99)00215-0.","journal-title":"Am J Hypertens"},{"key":"524_CR61","doi-asserted-by":"crossref","unstructured":"A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension--The GLANT Study. Study Group on Long-term Antihypertensive Therapy. Hypertens Res. 1995, 18: 235-244. 10.1291\/hypres.18.235.","DOI":"10.1291\/hypres.18.235"},{"key":"524_CR62","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1161\/01.CIR.0000090572.51900.92","volume":"108","author":"CD Furberg","year":"2003","unstructured":"Furberg CD, Psaty BM: Should evidence-based proof of drug efficacy be extrapolated to a \"class of agents\"?. Circulation. 2003, 108: 2608-2610. 10.1161\/01.CIR.0000090572.51900.92.","journal-title":"Circulation"},{"key":"524_CR63","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1524-6175.2006.04482.x","volume":"7","author":"DA Sica","year":"2005","unstructured":"Sica DA: Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J Clin Hypertens (Greenwich). 2005, 7: 21-26.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"524_CR64","volume-title":"Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Total Cardiovascular risk","author":"World Health Organization","year":"2007","unstructured":"World Health Organization: Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Total Cardiovascular risk. 2007, Geneva: World Health Organization"},{"key":"524_CR65","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","volume":"326","author":"J Lexchin","year":"2003","unstructured":"Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003, 326: 1167-1170. 10.1136\/bmj.326.7400.1167.","journal-title":"BMJ"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-10-33.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1741-7015-10-33\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-10-33.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T16:55:22Z","timestamp":1497977722000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-10-33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,5]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["524"],"URL":"https:\/\/doi.org\/10.1186\/1741-7015-10-33","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,5]]},"article-number":"33"}}